Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Amgen at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Amgen exhibits at Booth 3438 at ASH 2026 in New Orleans. Amgen supports a symposium on acute lymphoblastic leukemia and the order in which to use its treatments. Experts debate the path from asparaginase to cellular therapy now that minimal residual disease testing guides decisions.

OrganizationASH 2026 Attendance
Amgen
Thousand Oaks, CA
Large pharma
Biotechnology company, founded in 1980, that discovers, develops and manufactures human therapeutics for serious illnesses, including blood cancers.
Booth
Exhibiting at Booth 3438
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
3:00pm–6:00pm
Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era
Ordering acute lymphoblastic leukemia therapies, from asparaginase to bispecifics and CAR-T, guided by sensitive residual disease testing.
Leukemias

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Amgen

Tell us what you sell and we’ll find the people at Amgen most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction